Overall survival in patients with platinum- sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo- controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589.

Author: Ledermann JA

Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO-AGO intergroup Trial-TRIAS

Author: Jalid Sehouli